Recor, Medtronic share the state of Renal Denervation. Can Alva Health reduce the danger of strokes?
In this episode we’ll explore potentially life-saving treatments for hypertension and stroke.
First, we’ll talk with Sandra Saldana, CEO of the start-up Alva Health, which is developing a wearable system that can detect strokes. Alva Health won the 2021 Global Competition of the Medtech Innovator program.
Then we’ll explore renal denervation, the exciting but vexing method of lowering hypertension by ablating nerves in the kidney.
We’ll talk to the leaders in this space including Andy Weiss, CEO of Recor Medical, a division of Otsuka Holdings, that’s developing the Paradise Renal Denervation system.
Weiss, a medtech veteran, shares his long-term views, one why he still sees Renal Denervation as a game-changer.
Then, we’ll run an excerpt of the MedtronicTalks podcast interview with Jason Weidman, senior vice president and president of the coronary and renal denervation business at Medtronic.
Weidman details Medtronic’s latest regulatory hiccups but, like Weiss, explains why he sees renal denervation as an important new therapy that can save the lives of people struggling to control their hypertension.
You can listen to the entire interview with Weidman here. https://www.devicetalks.com/weidman-talks-us-through-the-long-road-to-get-symplicity-ready-to-help-patients-with-hypertension/.
First, we’ll talk with Sandra Saldana, CEO of the start-up Alva Health, which is developing a wearable system that can detect strokes. Alva Health won the 2021 Global Competition of the Medtech Innovator program.
Then we’ll explore renal denervation, the exciting but vexing method of lowering hypertension by ablating nerves in the kidney.
We’ll talk to the leaders in this space including Andy Weiss, CEO of Recor Medical, a division of Otsuka Holdings, that’s developing the Paradise Renal Denervation system.
Weiss, a medtech veteran, shares his long-term views, one why he still sees Renal Denervation as a game-changer.
Then, we’ll run an excerpt of the MedtronicTalks podcast interview with Jason Weidman, senior vice president and president of the coronary and renal denervation business at Medtronic.
Weidman details Medtronic’s latest regulatory hiccups but, like Weiss, explains why he sees renal denervation as an important new therapy that can save the lives of people struggling to control their hypertension.
You can listen to the entire interview with Weidman here. https://www.devicetalks.com/weidman-talks-us-through-the-long-road-to-get-symplicity-ready-to-help-patients-with-hypertension/.
Activity